Clinical trials
Cell Therapy clinical trials
Below are recruiting cell therapy clinical trials, each written for real people, not researchers. We’re tracking 1,068 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06369389Recruiting
Real-world care for blood cancer patients receiving CAR-T therapy
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
Toulouse, CHU de ToulouseAges 18 years+ - NCT07198867RecruitingPhase 1
A-CAR028 for relapsed or refractory AML
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07173322Recruiting
How CAR-T cell therapy affects fertility: a patient survey
This study is a survey to understand how CAR-T cell therapy might affect fertility. If you have had CAR-T cell treatment, your answers can help doctors learn more about its long-term effects.
Rye, New YorkAges 18 years+ - NCT07120633Recruiting
CAR-T cell therapy plus BTK inhibitor for high-risk CLL/SLL
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
Xuzhou, JiangsuAges 18 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06946485RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Nanjing, JiangsuAges 18–65 - NCT05481502Recruiting
Study looks at immune markers after cell therapy
This study collects immune and tumor-related samples to learn what predicts response to adoptive cell therapy (a treatment using immune cells). If you (or your child) are eligible, you may help researchers understand who benefits and why.
Villejuif, Val De MarneAges 2 years+ - NCT06885710RecruitingPhase 1
T cell therapy with antivirals for chronic hepatitis B
This study tests a new treatment that uses your own immune cells (T cells) modified to attack the hepatitis B virus, combined with standard antiviral medication. It is for people with chronic hepatitis B who have a specific HLA type and no advanced liver scarring.
ShanghaiAges 18–65 - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06775964RecruitingPhase 1/Phase 2
Stem cell therapy for early Alzheimer's disease
This trial tests a stem cell treatment for people with early-stage Alzheimer's disease. It aims to see if the treatment can help slow memory loss or other symptoms. You must have a specific blood test showing inflammation in the body to qualify.
Houston, TexasAges 60–80 - NCT06762431RecruitingPhase 1/Phase 2
CAR T-cell therapy plus lenalidomide for CLL
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Vitebsk, Select A StateAges 18 years+ - NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06710288RecruitingPhase 2
Immune cell therapy plus chemo for platinum-resistant ovarian cancer
This trial tests a new combination therapy for advanced ovarian cancer that has stopped responding to platinum-based chemo. You will receive your own immune cells (M-CENK) boosted with an immune stimulator (N-803) plus chemotherapy (gemcitabine) to see if this helps fight the cancer.
El Segundo, CaliforniaAges 18–85 - NCT06671275Enrolling by invitationPhase 1
Testing CUD005 Injection for Advanced Liver Cirrhosis
This study tests an injection called CUD005 for people with advanced liver cirrhosis that is causing complications. The goal is to see if it is safe and can help improve liver function.
Hefei, AnhuiAges 18–75 - NCT06665295Recruiting
THRIVE-CAR-T digital app for CAR-T patients
This trial tests a digital app to support patients receiving CAR-T therapy. It may help you track symptoms and communicate with your care team.
Boston, MassachusettsAges 18 years+ - NCT06616727Enrolling by invitationPhase 1
CAR-T cell therapy for recurrent glioblastoma
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
BeijingAges 18 years+ - NCT06579469Recruiting
Study of later effects of CAR T cell therapy
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
Aurora, ColoradoAges Up to 30 years - NCT06552169RecruitingPhase 2
Treg cell therapy to lower anti-rejection meds after kidney transplant
This trial tests whether adding a special type of immune cell (Treg cells) to standard therapy can help kidney transplant recipients safely take lower doses of anti-rejection medicines. It is for people who are getting a kidney from a living donor.
Phoenix, ArizonaAges 18–65 - NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Boston, MassachusettsAges 18 years+
Hear when a new Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cell therapy?
- Yes. Clin2 currently lists 1,068 recruiting cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.